Abbreviations: AF ϭ atrial fibrillation; INR ϭ international normalized ratio; NSR ϭ normal sinus rhythm; TEE ϭ transesophageal echocardiography A 78-year-old man presented to his personal physician for a yearly examination. He was totally asymptomatic. Findings of a physical examination performed 1 year previously were normal, and an ECG displayed normal sinus rhythm (NSR) and minor nonspecific T-wave changes. Five years previously, he was found to have mild systemic hypertension and was administered combined hydochlorothiazide (25 mg) and triamterene (37.5 mg) daily with satisfactory control of the BP throughout this time period.
A 78-year-old man presented to his personal physician for a yearly examination. He was totally asymptomatic. Findings of a physical examination performed 1 year previously were normal, and an ECG displayed normal sinus rhythm (NSR) and minor nonspecific T-wave changes. Five years previously, he was found to have mild systemic hypertension and was administered combined hydochlorothiazide (25 mg) and triamterene (37.5 mg) daily with satisfactory control of the BP throughout this time period.
Physical examination disclosed a BP of 140/80 mm Hg and an irregular cardiac rhythm, at the average rate of 115 beats/min. The cardiac findings were otherwise normal, and the remainder of the general examination was also normal. ECG disclosed atrial fibrillation (AF) with a moderate ventricular response rate of 100 to 120 beats/min. Minor T-wave abnormality was again found but did not differ significantly from previous patterns. An echocardiogram was performed and demonstrated a normalsized left ventricle with a normal contraction pattern (estimated ejection fraction, 56%). This chamber demonstrated mild hypertrophy (wall thickness, 1.3 cm). Mild left atrial dilatation was observed (diameter, 4.2 cm), and the remainder of the examination was normal, including the absence of flow abnormalities by intracardiac Doppler echocardiographic interrogation. Additional test results included a normal chest radiograph and a normal blood profile (CBC count, general chemistry values, electrolytes, and lipid profile). 1. This patient presents a common situation, where asymptomatic AF is discovered on routine examination. Prevalent in this age group, AF occurs in up to 8 to 15% of those Ͼ 80 years of age. The etiology in this patient, in addition to aging, may be hypertension, although other causes should be considered, especially hyperthyroidism.
Questions for Consultants
My approach to any patient newly diagnosed with AF is to first explain that AF is a chronic disease, and the goal of therapy is to reduce the frequency and severity of the recurrences. Even if the patient considers himself "asymptomatic," he may be sur-prised with the improvement after conversion. Therefore, when the AF is recent in onset (in this case some time in the last year), I generally recommend at least one trial of cardioversion. The relatively small left atrium (4.2 cm, with "normal" up to 4.0 cm in most laboratories) is encouraging for conversion and maintenance of sinus mechanism, although even greatly enlarged atria can support sinus mechanism and may deserve a trial at conversion. After conversion, if sinus rhythm was not maintained, and if the patient felt no better in sinus rhythm, I may suspend efforts to convert the rhythm. On the other hand, if the patient felt improved with sinus rhythm, he would more likely be interested in pursuing further efforts at maintaining sinus rhythm.
I would administer an atrioventricular nodal-blocking agent-either a ␤-blocker or calcium channelblocking agent-because the ventricular rate is high.
2. The patient likely has been in AF for Ͼ 48 h, so efforts to minimize the risk of embolic complication of AF must be pursued before conversion. The traditional approach of 3 weeks with international normalized ratio (INR) Ͼ 2.0 before cardioversion results in a very small risk of embolism. An alternate and potentially effective approach that is under investigation involves treatment with heparin, and conversion only after TEE rules out left atrial thrombus.
3. Typically I do not administer an antiarrhythmic medication for the first episode of AF. Rather, I let the patient demonstrate a need for this therapy by waiting until there is a recurrence of AF.
If a drug were to be used, I would favor either propafenone or sotalol as first choice. Both of these drugs are a bit less effective than amiodarone, although likewise, their noncardiac side effects are far less. Dofetilide has been shown to be relatively safe and well tolerated, even with heart disease, although clinical experience is limited.
4. I generally admit patients to the hospital for antiarrhythmic drug initiation except for dosing of amiodarone (because amiodarone has little risk of proarrhythmia). Sotalol and dofetilide are labeled only for inpatient administration. I start other antiarrhythmic drugs (propafenone or flecainide) on an outpatient basis when the heart is normal and the patient is in sinus mechanism; during AF, the rhythm can organize to atrial flutter and result in rapid conduction to the ventricles, especially if AV nodal blockade is inadequate.
5. The issue of how long to anticoagulate after conversion is complex. The absolute minimum after conversion (whether or not a TEE was performed) is 4 weeks with INR Ͼ 2.0. I favor longer, or indefinite, anticoagulation. This longer duration of antithrombotic therapy is based on several factors. First, a recent Stroke Prevention in Atrial Fibrillation metaanalysis 1 demonstrated that patients with intermittent AF have similar risk (and risk factors) for stroke when compared with patients in permanent AF. Second, conversion and maintenance of sinus mechanism have never been shown to reduce the risk of stroke from AF; only warfarin and, to a lesser degree, aspirin therapies reduce the risk of embolic complications. Third, asymptomatic recurrence of AF is likely. And fourth, previous data 2 show asymptomatic AF may be up to 12 times more frequent than symptomatic AF, even in patients with "symptomatic" paroxysmal AF. The data to guide us on detection of asymptomatic AF are scant; when compelled to consider discontinuation of warfarin therapy, I personally perform a 24-h Holter ECG as a "snapshot" to scan for AF.
James A. Reiffel, MD, New York, NY
The overall approach to management of this patient resembles that of most patients with AF: seek a correctable cause or modifiable underlying disorder, control the ventricular rate, consider the appropriate anticoagulation regimen, and consider the question of pursuit of sinus rhythm (rhythm control) vs allowing the patient to remain in AF (rate control plus anticoagulation). For this patient, thyroid function should also have been assessed. Although the results are usually normal, hyperthyroidism and hypothyroidism (the latter not rare in the elderly) may cause AF and be remediable. For rate control, digitalis, ␤-blockers, or verapamil/diltiazem may be considered (in younger patients, digitalis is of less value because it is rarely effective in active individuals). In this patient, a ␤-blocker, verapamil, or diltiazem (particularly the calcium channel blockers) might also suffice for BP control and, therefore, replace his diuretic therapy.
Because this is the first known episode of AF in this patient, an attempt at restoration of sinus rhythm is reasonable, with the hope that (1) this AF episode was "an electrical accident" that may not recur, or might recur so infrequently that only intermittent cardioversion might be considered; (2) the embolic risk might be reduced if NSR were maintained (though this has not been proven). Because the duration of AF is unknown in this patient, cardioversion should not be performed until he has been anticoagulated to an INR of 2.0 to 3.0 for at least 3 to 4 weeks. Were he to be symptomatic from his AF, and were the symptoms so annoying despite rate control as to render earlier cardioversion preferable if safe, then TEE-guided cardioversion could be considered (with early cardioversion if no clot or "smoke" on TEE). Regardless of whether cardioversion was TEE guided or not, this patient should be kept on warfarin therapy for life, if no contraindication exists, as he has multiple risk markers (including age and hypertension) for embolic risk with AF, and as his asymptomatic AF can preclude early recognition of recurrence and therefore leave him at risk for an embolic event as his next presentation. Alternatively, if he were highly reliable and could accurately check his pulse daily, warfarin therapy might be discontinued after 1 to 3 months (but not before 4 weeks), as long as he were to report immediately any sign of recurrent AF.
Were the patient to be converted, one might consider the use of an antiarrhythmic drug regimen to help maintain NSR. However, my general bias is not to do this unless AF recurrence is early, frequent, or highly likely, because infrequent events may be better managed by intermittent cardioversion than by daily antiarrhythmics, as impact on quality of life may be better. However, because his AF may be relatively long-standing, some would argue for a short (eg, 3 months) course of an antiarrhythmic drug in hopes of holding NSR long enough to allow the atria to remodel back toward normal. During AF, atrial remodeling occurs. This results in atrial enlargement and in shortening of refractory periods, changes that facilitate AF maintenance. It is hoped that these may be reversible with prolonged periods of sinus rhythm, which itself may then help maintain sinus rhythm. Some data exist to suggest that this may be the case.
As to that antiarrhythmic drug to consider, several algorithms have been published recently that are remarkably concordant. 3, 4 All are based primarily on choosing a first-line agent that is least likely to be organ toxic or proarrhythmic in the individual patient. A low-to no-organ toxic risk is a feature of sotalol, propafenone, flecainide, and dofetilide. Proarrhythmic risk depends largely on an interaction of the pharmacodynamic properties of a drug and the nature and severity of any structural heart disease (ventricular) present. If ischemia were excluded in this patient who has mild hypertensive disease with some mild left ventricular hypertrophy, propafenone would be the optimal first choice with sotalol as the next choice. 3, 4 Were his ventricle entirely normal as in lone AF, flecainide could also be considered. Were ischemia to be present, sotalol would be first choice, with dofetilide plus a ratecontrolling agent as a less convenient (two drug) alternative, and amiodarone would be a second-line choice. However, with all class III antiarrhythmics, it is imperative to avoid hypokalemia and hypomagnesemia; thus, I would use caution in the presence of his diuretics, were they still needed.
When antiarrhythmics are used for AF, the question as to whether to admit to the hospital for initiation always arises. 5 It is mandatory for dofetilide. It is indicated in the package inset for sotalol but the literature supports outpatient initiation in patients who are in NSR and have no torsade de pointes risk factors. [3] [4] [5] It is indicated for quinidine. However, inpatient initiation is not mandated for flecainide or propafenone, which are only approved for AF therapy in patients without structural heart disease or conduction-system disorders. The references listed [3] [4] [5] provide greater details. Procainamide, disopyramide, and amiodarone are not approved for AF; thus, sites of initiation for this purpose are not discussed in their package inserts. In general, procainamide and disopyramide should probably be treated like quinidine, whereas for most patients, in-hospital initiation for amiodarone is impractical. Close monitoring, as with transtelephonic with ECG monitoring, is advisable when antiarrhythmics are begun in the outpatient setting. Finally, returning to this patient, the probability is reasonably high that, because of his age and hypertension, AF will be recurrent. And, because it is entirely asymptomatic, long-term warfarin therapy and rate control without any pursuit of cardioversion and sinus rhythm would clearly be a reasonable and acceptable alternative approach in this individual.
Editor's Comments
This patient was administered warfarin for 4 weeks, during which his ventricular rate response was slowed to 70 to 80 beats/min with the use of metoprolol therapy. He then received electrical cardioversion as an outpatient, and this restored NSR. The warfarin and metoprolol therapy were continued, and during the initial follow-up period of 6 months, he has maintained NSR. He noted no change in his subjective sense of well being. In this instance, there was no elective use of additional drugs such as propafenone. The current plan is to continue the warfarin and metoprolol therapy permanently, for if AF were to recur asymptomatically, these drugs would continue to prevent thromboemboli and provide rate control. In addition, metoprolol therapy recently has been shown to reduce the incidence of recurrences of AF after NSR has been established. 6 The common occurrence of AF in our aging population accounts for the increasing attention to this subject paid by the medical community. Both Drs. Page and Reiffel have provided important contributions that have helped to shape medical thought on this matter. Their substantial agreement, as well as that of others, has laid the groundwork for greater uniformity in management.
Control of the ventricular response rate and proper use of anticoagulants are of paramount importance and are well covered in the discussions here. For a patient without significant structural heart disease, outpatient use of such drugs as propafenone and flecainide after electrical counterschock conversion can be employed at the discretion of the clinician, although this was not done in this instance. Unfortunately, under any circumstance, relapse into AF is common. At any point, therefore, the most cost-effective strategy would be to allow the patient to remain in AF and to employ anticoagulants, controlling the ventricular rate response pharmacologically, as suggested by Dr. Reiffel. We believe that a careful history would aid in determining whether, despite the presence of AF, the patient is truly asymptomatic, and therefore, a better candidate for this latter option, even from the very outset of management.
